/GOVX
GOVX Stock - GeoVax Labs, Inc.
Healthcare|BiotechnologyNASDAQ
$0.16-33.69%
$0.08 (-33.69%) • Dec 19
45
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+2412.6%upside
Target: $4.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for GOVX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.16 – $0.16
TARGET (TP)$4.00
STOP LOSS$0.15
RISK/REWARD1:417.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta3.64
52W High$2.75
52W Low$0.12
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $3.95M | N/A | $81,526 | $385,501 | $1.82M |
| Gross Profit | $3.86M | $-20,720,766 | $-9,041,953 | $385,501 | $1.82M |
| Gross Margin | 97.6% | N/A | -11090.9% | 100.0% | 100.0% |
| Operating Income | $-25,144,280 | $-26,742,939 | $-14,028,564 | $-18,745,823 | $-2,816,815 |
| Net Income | $-24,992,296 | $-25,966,762 | $-14,021,125 | $-18,570,317 | $-2,958,068 |
| Net Margin | -632.0% | N/A | -17198.3% | -4817.2% | -162.2% |
| EPS | $-4.82 | $-10.22 | $-5.52 | $-7.30 | $-1.16 |
Company Overview
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
4 Bullish0 Neutral/Bearish
Price Targets
$14
Average Target
↑ 8929.5% Upside
Now
$9
Low
$14
Average
$20
High
Based on 4 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| April 15th 2025 | D. Boral Capital | Reiterated | Buy | $14← $18 |
| April 15th 2025 | Alliance Global Partners | Reiterated | Buy | $8.5← $15 |
| November 11th 2024 | Alliance Global Partners | Initiation | Buy | $15 |
| July 16th 2024 | ROTH MKM | Initiation | Buy | $20 |
Earnings History & Surprises
GOVXBeat Rate
39%
Last 18 quarters
Avg Surprise
-708.2%
EPS vs Estimate
Beats / Misses
7/11
Last 12 quarters
Latest EPS
$-0.31
Q4 2025
EPS Surprise History
Q1 24
-389.2%
$-13.60vs$-2.78
Q2 24
+55.6%
$-2.47vs$-5.56
Q3 24
+22.6%
$-1.99vs$-2.57
Q4 24
+29.5%
$-0.91vs$-1.29
Q1 25
+62.0%
$-0.30vs$-0.79
Q2 25
+23.7%
$-0.45vs$-0.59
Q3 25
+14.6%
$-0.35vs$-0.41
Q4 25
-29.2%
$-0.31vs$-0.24
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 26, 2026 | $-0.29 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.24 | $-0.31 | -29.2% | ✗ MISS |
Q3 2025 | Jul 28, 2025 | $-0.41 | $-0.35 | +14.6% | ✓ BEAT |
Q2 2025 | May 1, 2025 | $-0.59 | $-0.45 | +23.7% | ✓ BEAT |
Q1 2025 | Mar 27, 2025 | $-0.79 | $-0.30 | +62.0% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-1.29 | $-0.91 | +29.5% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $-2.57 | $-1.99 | +22.6% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-5.56 | $-2.47 | +55.6% | ✓ BEAT |
Q1 2024 | Feb 29, 2024 | $-2.78 | $-13.60 | -389.2% | ✗ MISS |
Q4 2023 | Nov 8, 2023 | $-2.55 | $-4.80 | -88.2% | ✗ MISS |
Q3 2023 | Aug 9, 2023 | $-2.40 | $-3.30 | -37.5% | ✗ MISS |
Q2 2023 | May 4, 2023 | $-2.85 | $-2.25 | +21.1% | ✓ BEAT |
Q1 2023 | Mar 23, 2023 | $-2.55 | $-3.00 | -17.6% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $-1.80 | $-2.55 | -41.7% | ✗ MISS |
Q3 2022 | Aug 3, 2022 | $-0.32 | $-2.70 | -743.8% | ✗ MISS |
Q2 2022 | Apr 27, 2022 | $-0.31 | $-5.10 | -1545.2% | ✗ MISS |
Q1 2022 | Mar 9, 2022 | $-0.40 | $-33.58 | -8295.0% | ✗ MISS |
Q4 2021 | Nov 11, 2021 | $-0.37 | $-4.65 | -1156.8% | ✗ MISS |
Q3 2021 | Aug 11, 2021 | $-0.43 | $-3.15 | -632.6% | ✗ MISS |
Q2 2021 | May 6, 2021 | — | $-4.35 | — | — |
Latest News
GeoVax Labs Files Prospectus For Best-Efforts Offering Of 18,292,683 Units And Pre-Funded Units With Warrants
➖ NeutralBenzinga•Dec 12, 2025, 10:42 PM
D. Boral Capital Maintains Buy on Geovax Labs, Lowers Price Target to $6
➖ NeutralBenzinga•Nov 19, 2025, 01:12 PM•Also:
Geovax Labs Q3 EPS $(0.31) Misses $(0.25) Estimate
📉 NegativeBenzinga•Nov 13, 2025, 09:07 PM
D. Boral Capital Maintains Buy on Geovax Labs, Maintains $9 Price Target
📈 PositiveBenzinga•Sep 26, 2025, 11:25 AM
Shares of vaccine companies are trading lower following a Daily Beast report suggesting that President Trump and Health and Human Services Robert F. Kennedy, Jr. will ban Covid-19 vaccines "within months.
📉 NegativeBenzinga•Aug 25, 2025, 05:50 PM•Also: , ,
Frequently Asked Questions about GOVX
What is GOVX's current stock price?
GeoVax Labs, Inc. (GOVX) is currently trading at $0.16 per share. The stock has moved -33.69% today.
What is the analyst price target for GOVX?
The average analyst price target for GOVX is $4.00, based on 1 analyst.
What sector is GeoVax Labs, Inc. in?
GeoVax Labs, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is GOVX's market cap?
GeoVax Labs, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does GOVX pay dividends?
No, GeoVax Labs, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADAP
Adaptimmune Therapeutics plc
$0.05
Mkt Cap: $0.0B
ADTX
Aditxt, Inc.
$1.17
Mkt Cap: $0.0B
AIMD
Ainos, Inc.
$2.11
Mkt Cap: $0.0B
ANL
Adlai Nortye Ltd.
$1.52
Mkt Cap: $0.0B
APLM
Apollomics, Inc.
$16.73
Mkt Cap: $0.0B
BLRX
BioLineRx Ltd.
$3.04
Mkt Cap: $0.0B
ICU
SeaStar Medical Holding Corporation
$0.24
Mkt Cap: $0.0B
LNAI
Lunai Bioworks Inc.
$1.05
Mkt Cap: $0.0B
MBRX
Moleculin Biotech, Inc.
$3.90
Mkt Cap: $0.0B
THAR
Tharimmune, Inc.
$2.32
Mkt Cap: $0.1B
Explore stocks similar to GOVX for comparison